Publikationen 2011
J. Küblbeck; J. Jyrkkärinne; F. Molnar; T. Kuningas; J. Patel; B. Windshügel;T. Nevalainen; T. Laitinen; W. Sippl; A. Poso; P. Honkakoski
New in Vitro Tools to Study Human Constitutive Androstane Receptor (CAR) Biology: Discovery and Comparison of Human CAR Inverse Agonists. Molecular Pharmaceutics 8, 2424-2433, 2011. doi:10.1021/mp2003658
E. Aehle; U. Mueller; P. C. Eklund; S. M. Willfoer; W. Sippl; B. Draeger
Lignans as food constituents with estrogen and antiestrogen activity.
Phytochemistry (Elsevier) 72, 2396-2405, 2011. doi:10.1016/j.phytochem.2011.08.013
J. Bajorath; M. L. Barreca; A. Bender; R. Bryce; M.Hutter; Ch. Laggner; Ch.Laughton; Y. Martin; J. Mitchell; A. Padova; S. Renner; P. M. Selzer; W. Shermann; W. Sippl; Ch. Taft; T. Tuccinardi; G. Vistoli; P. Willett
Ask the experts: focus on computational chemistry
Future medicinal chemistry, 3, 909-21, 2011. doi:10.4155/fmc.11.57
R. Heinke, U. Uciechowska, M. Jung, W. Sippl. Target-based virtual screening on small molecule protein binding sites. In: C. Sotriffer (Ed.), Virtual Screening - Principles, Challenges, and Practical Guidelines
Wiley-VCH, Weinheim, pp. 411-432, 2011.
W. Sippl, V. Collura, F. Colland. Ubiquitin specific proteases as cancer drug targets. Future Oncology, 7, 619-632, 2011. doi:10.2217/fon.11.39
S. Schlimme, A.-T.Hauser, V. Carafa, R. Heinke, S. Kannan, D. A. Stolfa, S. Cellamare, A. Carotti, L. Altucci, M. Jung and W. Sippl. Carbamat prodrug concept for hydroxamate HDAC inhibitors. Chem. Med. Chem. 6, 1193-1198, 2011. doi:10.1002/cmdc.201100007
M. Krug, K. Wichapong, G. Erlenkamp, W. Sippl, C. Schächtele, F. Totzke and A. Hilgeroth. Discovery of 4-Benzylamino-Substituted α-Carbolines as a Novel Class of Receptor Tyrosine Kinase Inhibitors. Chem. Med. Chem. 6, 63-72, 2011. doi:10.1002/cmdc.201000384.
Wolfgang Sippl; Manfred Jung. Epigenetic drug discovery special issue. Bioorganic & Medicinal Chemistry 19, 3603-3604, 2011. doi:10.1016/j.bmc.2011.05.053.
R. Heinke, L. Carlino,S. Kannan, M. Jung, W. Sippl. Computer- and structure-based lead design for epignetic targets. Bioorganic & Medicinal Chemistry 19(12), 3605-3615, 2011. doi:10.1016/j.bmc.2011.01.029
T. Pesnot, J. Kempter, J. Schemies, G. Pergolizzi, U. Uciechowska, W. Sippl, M. Jung, and G. K. Wagner. A Two-Step Synthesis of Novel, Bioactive Derivatives of the Ubiquitous Cofactor NAD. J. Med. Chem. 54, 3492-3499, 2011. doi:10.1021/jm1013852.
E. Bissinger, R. Heinke, A. Spannhoff, A. Eberlin, E. Metzger, R. Schüle, M. T. Bedford, W. Sippl, M. Jung. Acyl Derivatives of p-Aminosulfonamides and Dapsone as new Inhibitors of the Arginine Methyltransferase hPRMT1. Bioorganic & Medicinal Chemistry 19, 3717-3731, 2011. doi:10.1016/j.bmc.2011.02.032
S. Furdas, S. Shekfeh, E. Bissinger, J. Wagner, S. Schlimme, P, J. Brown, C. H. Arrowsmith, M. M. Mangos, V. Valkov, M. Hendzel, M. Jung, W. Sippl. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorganic & Medicinal Chemistry 19, 3678-33689, 2011. doi:10.1016/j.bmc.2011.01.063
B. Maurer, U.Mathias, P. Papatheodorou, S. Shekfeh, J. Orth, T. Jank, C. Schwan, W. Sippl, K. Aktories, M. Jung. From cosubstrate similarity to inhibitor diversity-inhibitors of ADP-ribosyltransferases from kinase inhibitor screening. Mol Biosyst. 7, 799-808, 2011. doi:10.1039/c0mb00151a.
A. Heinz, S. Taddese, W. Sippl, R.H. Neubert, C.E. Schmelzer. Insights into the degradation of human elastin by matrilysin-1. Biochimie. 93, 187-94, 2011. doi:10.1016/j.biochi.2010.09.011.
W. Becker, W. Sippl. Activation, regulation and inhibition of DYRK1A
FEBS J., 278, 246-56, 2011. doi:10.1111/j.1742-4658.2010.07956.x.